![3期临床失败,对照组疗效异常升高,默克BTKi被绊了一跤……](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
![3期临床失败,对照组疗效异常升高,默克BTKi被绊了一跤……](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
这样市场前景巨大的靶点,当然有许多药企也想要挤进这个市场,分一杯羹。但是BTK抑制剂在血液瘤领域的竞争已经够激烈了,因此,不少药企开始开发BTK抑制剂的新适应症。
2023年8月,诺华宣布,其在研BTK抑制剂Remibrutinib治疗慢性自发性荨麻疹(CSU)的两项三期临床REMIX-1、REMIX-2达到了所有主要和次要终点,并且安全性良好,总体不良事件发生率与安慰剂相当(瑞布替尼为64.0%,安慰剂为64.7%)。
诺华Remibrutinib的这次成功,让BTK抑制剂成功敲开了自免领域的大门,但是在自免这条路上,BTK抑制剂仍然走得磕磕绊绊……
![3期临床失败,对照组疗效异常升高,默克BTKi被绊了一跤……](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
![3期临床失败,对照组疗效异常升高,默克BTKi被绊了一跤……](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
-
https://clinicaltrials.gov/study/NCT 04338022
-
file:///C:/Users/mengy/Downloads/F1_CMSC%202022%20SEL%20Poster%20(2).pdf
-
https://www.clinicaltrialsarena.com/news/merck-multiple-sclerosis-trials/?cf-view&cf-closed
-
https://www.merckgroup.com/en/news/evobrutinib-phase-lll.html
-
https://www.biospace.com/article/merck-kgaa-s-btk-inhibitor-fails-phase-iii-multiple-sclerosis-studies/
-
https://www.biospace.com/article/merck-kgaa-s-btk-inhibitor-fails-phase-iii-multiple-sclerosis-studies/
-
默克官网
-
其他公开资料
![3期临床失败,对照组疗效异常升高,默克BTKi被绊了一跤……](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
![3期临床失败,对照组疗效异常升高,默克BTKi被绊了一跤……](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
本篇文章来源于微信公众号: 药时代
发布者:haitao.zhao,转载请首先联系contact@drugtimes.cn获得授权